menu
    • menu
    [{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ORN-101","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Orna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Circular RNA-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Orna Therapeutics","amount2":3.6499999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":3.6499999999999999,"dosageForm":"","sponsorNew":"Orna Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"3","companyTruncated":"Orna Therapeutics \/ Merck & Co. Inc."}]

    Find Clinical Drug Pipeline Developments & Deals by Orna Therapeutics

    Menu

    Orna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orna Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Orna Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Circular RNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Merck & Co

                            Deal Size : $3,650.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

                            Details : Under the agreement, Merck will discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology by using Orna’s proprietary oRNA technology.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : $150.0 million

                            August 16, 2022

                            Lead Product(s) : Circular RNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Merck & Co

                            Deal Size : $3,650.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orna Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Orna Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORN-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orna Therapeutics to Present Novel, First-in-Class Circular RNA Data at Upcoming ASGCT 2022 Annual Meeting

                            Details : First in vivo studies for ORN-101, demonstrated the potential of Orna's circular RNA (oRNA™) platform in cancer, genetic disorders, and infectious diseases.

                            Brand Name : ORN-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : ORN-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth